Mp10-04 High Expression of Cancer-Derived Igg Is Associated With Poor Survival in Metastatic Clear Cell Renal Cell Carcinoma

You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) I (MP10)1 May 2024MP10-04 HIGH EXPRESSION OF CANCER-DERIVED IGG IS ASSOCIATED WITH POOR SURVIVAL IN METASTATIC CLEAR CELL RENAL CELL CARCINOMA Jie Wu, Hong-Lei Cui, Hong-Zhe Shi, and Jian-Zhong Shou Jie WuJie Wu , Hong-Lei CuiHong-Lei Cui , Hong-Zhe ShiHong-Zhe Shi , and Jian-Zhong ShouJian-Zhong Shou View All Author Informationhttps://doi.org/10.1097/01.JU.0001008588.39303.c9.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The treatment landscape of metastatic clear cell renal cell carcinoma (mccRCC) has evolved from cytokine regimens to targeted therapy, and now immunotherapy-based drug combinations over the past two decades. However, there is a lack of confirmed prognosis biomarkers for mccRCC patients. Immunoglobulin G (IgG), well known as immune molecule secreted by B cells, has recently been detected in various types of cancer cells, named as cancer-derived IgG. Notably, it has been demonstrated that IgG derived from epithelial cancer cells displays unique N-glycosylation, which is highly sialylated (SIgG). METHODS: In this study, we explored the expression of SIgG in mccRCC tissues using the monoclonal antibody RP215, and evaluated prognostic value SIgG in mccRCC patients. A total of 179 mccRCC patients with complete clinicopathological information and survival data were enrolled. Tissue microarray slides were then constructed for immunohistochemistry (IHC). The cohort distribution and clinical data were shown. The primary end point was overall survival (OS), defined as the time from initiation of systemic treatment to death or last follow-up. RESULTS: The results of IHC showed that SIgG was mainly expressed in the cell membrane and cytoplasm, and the high expression of SIgG was significant correlated with poor OS in mccRCC patients (HR=2.281, p<0.001. Moreover, based on multivariate Cox regression analysis, high SIgG expression was identified as an independent prognostic variable for OS in mccRCC patients (HR=2.110, p<0.001), as well as poor the International mRCC Database Consortium (IMDC) risk group (HR=2.123, p=0.018). The time-dependent ROC curve also suggested the promising prognostic value of SIgG, with a 5-year AUC of 0.679 for SIgG alone and 0.742 for SIgG combined with IMDC risk model. According to sub group analyses, the prognostic value of SIgG was more marked in patients with intermediate (HR=2.191, p=0.019) and poor (HR=2.111, p=0.058) IMDC risk group, and lung metastasis (HR=1.970, p=0.009). Notably, the prognostic value of SIgG was significant in both synchronous and metachronous metastasis patients. CONCLUSIONS: In this study, we found that SIgG was a reliable predictor for the outcome of mccRCC patients, and SIgG combined with IMDC risk model was a more effective prognostic model than IMDC risk group alone. Source of Funding: NA © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e138 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Jie Wu More articles by this author Hong-Lei Cui More articles by this author Hong-Zhe Shi More articles by this author Jian-Zhong Shou More articles by this author Expand All Advertisement PDF downloadLoading ...